Pharmaceutical

Arcus Biosciences obtains loan facility with Hercules C...

Arcus turned to Hercules Capital’s financing for support and to advance its HIF-...

Soleno wins FDA priority review for Prader-Willi therapy

The FDA also plans to hold an advisory committee for the DCCR therapy for Prader...

Oesophageal cancer: the global clinical trials landscap...

With new oesophageal cancer cases annually projected to increase by 80% before 2...

Navigator gains $100m in Series A funding for antibody ...

Navigator Medicines has secured $100m in a Series A financing round with the aim...

EC approves Astellas’ PADCEV for urothelial cancer

The European Commission has authorised Astellas Pharma's PADCEV regimen for the ...

Pfizer launches digital healthcare platform to streamli...

Pfizer has launched a new digital platform, PfizerForAll, aimed at simplifying t...

Eli Lilly’s Zepbound to be issued in single-dose vials ...

Eli Lilly has announced the availability of Zepbound (tirzepatide) in 2.5mg and ...

UCB to divest China neurology and allergy business for ...

UCB has entered a divestment agreement in China to sell its mature neurology and...

MSD snags European approval for pulmonary arterial hype...

Winrevair is the first approved activin signaling pathway-targeting therapy for ...

Celltrion’s SteQeyma receives EC approval for chronic i...

The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to ...

Invenra’s antibody gains US FDA designations for neurob...

Invenra received rare pediatric disease designation (RPDD) and orphan drug desig...

China NMPA grants approval for GenFleet’s fulzerasib to...

China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced no...

Janssen’s BALVERSA receives EC approval for metastatic ...

The European Commission (EC) has approved Janssen's BALVERSA as a treatment for ...

AstraZeneca may pull plug on UK vaccine manufacturing p...

AstraZeneca may relocate its vaccine manufacturing plans from the UK to US as th...

Eli Lilly doubles down on Oblique partnership for antib...

The two companies have expanded their agreement first inked in 2023, with a seco...

Jazz’s cannabidiol therapy flunks in Japanese Phase III...

Jazz’s cannabidiol oral solution, Epidiolex, is approved as an adjunct seizure t...